Brensocatib
FDA grants brensocatib priority review for bronchiectasis
The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a manufacturer-issued press release.
Brensocatib slows lung function decline, improves quality of life in bronchiectasis
Patients with non-cystic fibrosis bronchiectasis experienced less FEV1 and FVC decline and had improved quality of life with 52-week once-daily brensocatib vs. placebo, according to findings presented at the World Bronchiectasis Conference.
Brensocatib decreases annualized exacerbation rate in bronchiectasis
Among patients with non-cystic fibrosis bronchiectasis, once-daily brensocatib for 52 weeks lowered the annualized pulmonary exacerbation rate and was well tolerated, according to topline results from the ASPEN trial.
Top news of June: FDA bans marketing of Juul products; pulse oximetry accuracy; COVID-19
The Healio Editors compiled the most-read news in pulmonology posted in May.
Brensocatib did not improve clinical status in patients with severe COVID-19
SAN FRANCISCO — Brensocatib, an investigational oral inhibitor of dipeptidyl peptidase 1, did not improve the clinical status of patients hospitalized with severe COVID-19 at 29 days, according to results of the STOP-COVID19 trial.
Brensocatib prolongs time to first pulmonary exacerbation in patients with bronchiectasis
Treatment with brensocatib for 24 weeks significantly prolonged time to first pulmonary exacerbation in patients with non-cystic fibrosis bronchiectasis compared with placebo, according to results from the WILLOW study.